by Benzinga News-desk | Jun 29, 2026 | General
Topline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed or refractory (R/R)...
by Benzinga Insights | Jun 29, 2026 | General
Coca-Cola Consolidated (NASDAQ:COKE) has outperformed the market over the past 15 years by 12.91% on an annualized basis producing an average annual return of 25.0%. Currently, Coca-Cola Consolidated has a market capitalization of $12.80 billion. Buying $1000 In COKE:...
by Benzinga Insights | Jun 29, 2026 | General
Coca-Cola Consolidated (NASDAQ:COKE) has outperformed the market over the past 15 years by 12.91% on an annualized basis producing an average annual return of 25.0%. Currently, Coca-Cola Consolidated has a market capitalization of $12.80 billion. Buying $1000 In COKE:...
by Piero Cingari | Jun 29, 2026 | General
The defining bottleneck of the artificial-intelligence boom is no longer the graphics processor. It is the memory that sits next to it. That is the core argument of a Monday note from Jordi Visser, head of AI macro nexus at 22V Research. Borrowing a line from KAIST...
by Henry Khederian | Jun 29, 2026 | General
Sellas Life Sciences Group Inc (NASDAQ:SLS) shares are trading sharply higher by about 24% on Monday as the stock extends a breakout run that has traders focused on fresh highs and corporate updates. SELLAS Life Sciences shares are testing new highs. Why is SLS stock...
Recent Comments